We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sun Pharma recorded the considerable increment of 46% in its (unaudited) net profit to Rs 1158.9 mn in Q4 FY 2005-06 compared to the same period of 2004-05.
Swiss drugmaker Novartis will acquire NeuTec Pharma, a UK-based pharmaceutical company that specializes in the development of genetically recombinant antibodies, for $570 million in cash, the company reported.
Guyana is facing the possibility of no longer manufacturing its own antiretroviral (ARV) drugs because of mounting pressure from the international donor community for the drugs to come from an approved source or to undergo a bioequivalence test, according to local reports.
New Jersey-based Xechem International's new treatment for sickle cell disease (SCD) has been designated an orphan drug by the FDA, the company announced.
India-based Ranbaxy Pharmaceuticals has entered into an agreement with fellow Indian drugmaker Zenotech Laboratories to develop, submit for regulatory approval, and manufacture a total of 11 oncology products, which Ranbaxy will market as generic formulations in the U.S. and Canada.
Bioxel, a company which manufactures and markets taxane active pharmaceutical ingredients (APIs) used in chemotherapeutic drugs, has turned to two contract manufacturing companies to scale up production.
German biopharma firm Sandoz has won a landmark first-of its-kind biosimilar drug approval in the US after a long battle with the US Food and Drug Administration (FDA).
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced the achievement of a development milestone that is a subject of the Reformulation and New Product Agreement with Cypress Bioscience, Inc.
Degussa AG of Dusseldorf, Germany today announced that the company has signed a definitive agreement under which Gilead Sciences, Inc., of Foster City, California plans to acquire Degussa's subsidiary Raylo Chemicals Inc. with its assets at the Clover Bar site.